Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
0 hedge funds and large institutions have $0 invested in Viracta Therapeutics, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 7 closing their positions.
100% less funds holding
Funds holding: 7 → 0 (-7)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $3.8K → $0 (-$3.8K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$2.19K |
| 2 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$860 |
| 3 |
WA
WealthTrust Axiom
Wayne,
Pennsylvania
|
-$384 |
| 4 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$283 |
VIRX Hedge Fund Activity: Q2 2025 in Review
0 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2025, worth a combined $0 — down 100% from $3.8K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VIRX and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was XTX Topco, exiting entirely with an estimated $2.19K sold.
- 0 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2025, down from 7 in Q1 2025.
- Funds reported $0 of Viracta Therapeutics, Inc. Common Stock stock for Q2 2025, down 100% quarter-over-quarter.
- 0 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2025 and 7 closed out, a net change of -7 holders.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2025 was XTX Topco, an estimated $2.19K sold.
Based on aggregated 13F filings for Q2 2025.